BioGenCell presented its promising results from its First In Human (FIH) study in “no option’ CLI patients at the 45th Annual VEITH symposium on Vascular and Endovascular Issues, organized by the world-renowned Prof. Veith who is also on BioGenCell’s scientific advisory board.BioGenCell’s scientific advisor, Dr. Michael Frogel, an Associate Professor of Pediatrics at the Albert Einstein College of Medicine, Principal Investigator for the New York City Pediatric Disaster Coalition (PDC) and Medical Director of the Pediatric Disaster Mental Health Initiative at Maimonides Medical Center, NY, USA, gave the presentation in November to an audience of prominent vascular surgeons, interventional radiologists and interventional cardiologists interested in hearing more on the latest advances, changing concepts in diagnosis and management, pressing controversies and new techniques in medical fields.

Comments are closed.